Disease · EFO_0010072

toothache

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. toothache. Diseases, record EFO_0010072. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0010072

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: toothache
Open Targets ID: EFO_0010072
Other names: dental pain
Highest stage of its drugs: Approval, for 7 of its 22 drugs, from DailyMed

Source Open Targets

Drugs22

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IBUPROFEN	CHEMBL521	Small molecule	Approval	DailyMed	12	6	6	Drugs and targets
ACETAMINOPHEN	CHEMBL112	Small molecule	Approval	DailyMed	16	5	5	Drugs and targets
NAPROXEN	CHEMBL154	Small molecule	Approval	DailyMed	4	2	2	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Approval	DailyMed	7	0	0	Drugs and targets
BENZOCAINE	CHEMBL278172	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
DEXBROMPHENIRAMINE MALEATE	CHEMBL1200638	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
PHENYLEPHRINE HYDROCHLORIDE	CHEMBL1200339	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CODEINE	CHEMBL485	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ETORICOXIB	CHEMBL416146	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NAPROXEN SODIUM	CHEMBL1200806	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 22

See all 22 drugs

Targets25

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS2	Cyclooxygenase	8	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	6	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
OPRM1	Mu-type opioid receptor	3	Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta agonist	Phase 3	https://conductscience.org/library/genes/4988	Drugs and targets
SCN10A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker; Sodium channel protein type X alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6336	Drugs and targets
SCN4A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6329	Drugs and targets
SCN9A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker; Sodium channel protein type IX alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6335	Drugs and targets
ADRA1A	Adrenergic receptor alpha	2	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha	2	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha	2	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
SCN11A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Early phase 1	https://conductscience.org/library/genes/11280	Drugs and targets

1 to 10 of 25

See all 25 targets

Trials17

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00694369	A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)	Phase 3	588	2010-01-29	Postoperative Dental Pain	ACETAMINOPHEN, CODEINE, ETORICOXIB, IBUPROFEN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01075243	Post-operative Dental Pain Study Comparing Two Different Dosage of Analgesic Efficacy	Phase 4	401	2015-04-29	Post-surgical Dental Pain	ACETAMINOPHEN	Its record names the disease	ClinicalTrials.gov
NCT01389284	Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium	Phase 3	300	2013-05-07	Pain, Postoperative	NAPROXEN SODIUM	Its record names the disease	ClinicalTrials.gov
NCT00707057	Ibuprofen Extended-Release Dental Pain Study	Phase 3	256	2011-03-23	Pain, Post-Operative Pain, Third Molar Extraction	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT01229228	Study of Naproxen Capsules to Treat Dental Pain	Phase 2	254	2012-03-29	Dental Pain	NAPROXEN	Its record names the disease	ClinicalTrials.gov
NCT01529346	Efficacy Of PF-05089771 In Treating Postoperative Dental Pain	Phase 2	235	2018-06-01	Postoperative Dental Pain	IBUPROFEN, PF-05089771	Open Targets' reading of its record	ClinicalTrials.gov
NCT03441269	Adult Oral Ibuprofen Study for ED Pain Patients	Phase 4	225	2020-06-04	Pain, Acute	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT00964431	Phase 2 Study of Indomethacin Capsules to Treat Dental Pain	Phase 2	203	2012-03-30	Dental Pain	CELECOXIB, INDOMETHACIN	Its record names the disease	ClinicalTrials.gov
NCT00913627	Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain	Phase 2	196	2018-03-22	Pain	IBUPROFEN, NAPROXEN	Its record names the disease	ClinicalTrials.gov
NCT01512160	Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain	Phase 2	90	2013-06-28	Post-surgical Dental Pain	PF-04531083	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 17

See all 17 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ibuprofen 600mg ER vs Placebo: Durability of Effect as Measured by the Number of Subjects Achieving Meaningful Improvement in Pain Intensity Difference (PID) From Baseline at All Three Assessment Periods of 24, 36, and 48 Hours	123 of 169	47 of 87	256	NCT00707057	Trial comparisons
Ibuprofen 600mg ER vs Placebo: serious adverse events	0 of 169	0 of 87	256	NCT00707057	Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31383385	DERIVED	1	PubMed
26588111	DERIVED	1	PubMed
24127200	DERIVED	1	PubMed
23972577	DERIVED	1	PubMed
23247002	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0010072

GET https://conductscience.org/api/diseases/v1/EFO_0010072/drugs?page=2

API reference For AI assistants